Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $30.06, for a total value of $385,759.98. Following the completion of the sale, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $836,659.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Intersect ENT Inc (XENT) traded down $0.95 during midday trading on Tuesday, hitting $28.80. The stock had a trading volume of 333,431 shares, compared to its average volume of 291,532. Intersect ENT Inc has a fifty-two week low of $9.25 and a fifty-two week high of $33.25.

Intersect ENT (NASDAQ:XENT) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. The firm had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The firm’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) earnings per share. research analysts anticipate that Intersect ENT Inc will post -0.63 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Teachers Advisors LLC lifted its position in Intersect ENT by 7.5% in the second quarter. Teachers Advisors LLC now owns 66,492 shares of the medical equipment provider’s stock worth $1,858,000 after purchasing an additional 4,634 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Intersect ENT during the 2nd quarter valued at $331,000. Swiss National Bank lifted its position in shares of Intersect ENT by 23.7% during the 2nd quarter. Swiss National Bank now owns 42,800 shares of the medical equipment provider’s stock valued at $1,196,000 after acquiring an additional 8,200 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Intersect ENT by 23.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 185,117 shares of the medical equipment provider’s stock valued at $5,174,000 after acquiring an additional 34,577 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Intersect ENT by 3.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 139,377 shares of the medical equipment provider’s stock valued at $3,896,000 after acquiring an additional 5,033 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Several analysts recently weighed in on the company. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Northland Securities reaffirmed a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a report on Friday, November 3rd. Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Canaccord Genuity upped their target price on Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Finally, Bank of America upped their target price on Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a report on Monday, September 11th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $30.88.

WARNING: “Intersect ENT Inc (XENT) CFO Jeryl L. Hilleman Sells 12,833 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/intersect-ent-inc-xent-cfo-jeryl-l-hilleman-sells-12833-shares.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with MarketBeat.com's FREE daily email newsletter.